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Abstract: The spectrum and efficacy of available antileishmanial drugs is limited. In the present
work we evaluated in vitro the antiproliferative activity of 11 compounds based on tetradentate
polyamines compounds against three Leishmania species (L. braziliensis, L. donovani and L. infantum)
and the possible mechanism of action. We identified six compounds (3, 5, 6, 7, 8 and 10) effective
against all three Leishmania spp both on extracellular and intracellular forms. These six most active
leishmanicidal compounds also prevent the infection of host cells. Nevertheless, only compound 7 is
targeted against the Leishmania SOD. Meanwhile, on the glucose metabolism the tested compounds
have a species-specific effect on Leishmania spp.: L. braziliensis was affected mainly by 10 and 8,
L. donovani by 7, and L. infantum by 5 and 3. Finally, the cellular ultrastructure was mainly damaged
by 11 in the three Leishmania spp. studied. These identified antileishmania candidates constitute a
good alternative treatment and will be further studied.
Keywords: amastigote; antileishmania; antiproliferative; Leishmania spp.; promastigote; SOD;
tetradentate polyaminic compounds; ultrastructure
1. Introduction
Leishmaniasis are a group of complex sandfly-transmitted diseases caused by a protozoa parasite
from over 20 Leishmania species that affect mainly the poorest population of developing countries [1].
According to World Health Organization, leishmaniasis causes 20,000–30,000 deaths and 700,000–1
million new cases annually that impose a serious health problem worldwide. They are widely spread
in east Africa, Latin America, eastern Mediterranean region, south-east Asia region, and European
region by importing cases mainly from Africa and America. However, the principal etiological agents,
phlebotomine vectors, animal reservoirs and clinical syndromes in each continent may be different [1].
There are three predominant clinical forms. Cutaneous leishmaniasis (CL) presents itself by
self-healing erythematous papules and, therefore, is non-life-threatening. Mucosal or muco-cutaneous
leishmaniasis (MCL) causes deforming inflammation of the mucosa with non-self-healing ulcerations,
which can disseminate through the lymphatic system. In the last, visceral or kala-azar Leishmaniasis
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(VL), there are no apparent ulcerations, but the symptoms are much more severe. If left untreated, it is
a fatal disease characterized by irregular fever, malaise, weight loss, hepatosplenomegaly and anaemia
with or without lymphadenopathy, frequently associated with secondary infections [2]. Even after a
treatment, the disease reemerges or reappears as post-kala-azar dermic leishmaniasis (PKDL), causing
hypopigmentation, disperse dermic or epidermic inflammation and macular, popular or nodular rash.
People with PKDL are a potential source of kala-azar infection [1].
Leishmania braziliensis is one of the most representative species that cause MCL, and is mainly
active in Brazil, Colombia, Venezuela and the Andes range [3]. On the other hand, L. infantum is the
primary agent responsible for CL in the Mediterranean Basin (Spain, Greece and northern Africa) [4].
VL and PKDL are caused by L. donovani–L. infantum complex in the Old World and by L. infantum (syn.
L. chagasi) in the New World, although PKDL is extremely rare [5]. VL has by far the greatest impact,
not only because of the prevalence and lethality which placed leishmaniasis ninth in a global analysis
of infectious diseases. Also, there is a growing incidence of resistance against the first-line antimony
drugs and drug combinations in endemic regions [6].
The treatment depends on several factors such as type of disease, parasite species, concomitant
pathologies, and geographic location [1]. Apart from the increasing drug resistance, there are other
drawbacks that make the current treatment difficult, such as the administration method, a long
treatment period, high toxicity and cost and limited availability in endemic regions. The spectrum and
efficacy of available antileishmanial drugs is limited. The front-line drugs are pentavalent antimonial
compounds (sodium stibogluconate or Pentostam and meglumine antimoniate or Glucantime),
while amphotericin B, pentamidine and paromomycin (aminosidine) are used as second-line
chemotherapy. Other alternative antileishmanial medicines are miltefosine, azithromycin, allopurinol,
dapsone, sitamaquine, rifampicin or azole medicines: ketoconazole, fluconazole, itraconazole, none of
which were designed specifically as leishmaniasis treatment. Combining the drugs in order to create
a multidrug therapy may bring significant advantages and better therapeutic effects than each of
the components alone [7,8]. The treatment success depends of the clinical form of leishmaniasis,
the Leishmania spp. and the geographical region [9].
Target Product Profile (TPP), a planning tool for promising therapeutic candidates, takes into
account different factors (compound efficacy, delivery mode, dosage form, time of treatment, stability,
tolerability, safety, contraindications, and cost) [10]. A broad-spectrum activity, in terms of distinct
species and strains, should be considered as additional specificities for VL and CL [11,12].
Therefore, given the lack of appropriate treatments and the epidemiological impact of the disease,
the development of new drug candidates, safer and more effective, remains a priority. In this respect,
in the last decade our group has studied many potential leishmanicidal and trypanocidal compounds,
comprising natural extracts and newly synthesized compounds [13–15].
In our research, we try to develop molecules that are able to inhibit parasite-specific enzymes
such as the iron superoxide dismutase (Fe-SOD). The Fe-SOD plays a key role in the oxidative stress
defence mechanism in the trypanosomatid family, and this isoenzyme is not present in mammalian
cells. The typical mammalian superoxide dismutases are linked either to manganese or to copper/zinc
atoms (Mn-SOD or Cu/Zn-SOD). Mehlotra [16] has demonstrated that the parasitic protozoan survival
is closely related to the ability of Fe-SOD to decompose the superoxide radical originated by the host
cell. In this line, some of us have studied in depth during the last decade the redox properties of
polyaminic tetradentate compounds, including their corresponding Fe and Mn-based coordination
complexes, and their ability to create powerful oxidizing species upon fast reaction with hydrogen
peroxide [17]. Our starting point for the present study was to test the ability of this type of compounds
to cause a disruption of Fe-SOD activity, and therefore, to affect the viability of the parasite.
The major aim of the present work was to evaluate in vitro the antiproliferative activity of
11 tetradentate polyaminic compounds, fully stable in water and in cell cultures [17], against
promastigote and amastigote forms of three Leishmania spp. (L. braziliensis, L. donovani and L. infantum)
and their non-specific cytotoxicity against macrophages, as well as to perform infectivity assays on
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macrophage cells. Furthermore, we have studied the effect of the compounds on the ultrastructure of
Leishmania promastigotes by transmission electronic microscopy (TEM), the SOD-isoenzyme specificity
and the caused metabolic alterations by 1H-NMR analysis, specifically on the glycolytic pathway since
it is the prime energy source of the parasites.
2. Results
2.1. Selection of the Compounds Under Study
We selected two Fe-based complexes 1 and 2, four Mn-based complexes 3–6 and five polyamine
metal-free compounds 7–11. It was envisioned that the selected metal based compounds could generate
oxidizing species that may elude the protecting role of the Fe-SOD enzyme of the parasite. On the
other hand, the metal-free compounds were selected to understand the effect of the metal in some cases
(compounds 7, 9, 11) whereas 8 and 10 were tested for their known ability to strongly chelate transition
metals, aiming at disrupting the parasite metabolism by sequestering transition metals essential for
their viability, such as iron.
2.2. In Vitro Antileishmanial Activity
We have tested the in vitro inhibitory properties of 11 polyaminic compound complexes (Figure 1)
against the extra- and intracellular forms of three Leishmania spp., L. braziliensis, L. donovani and
L. infantum. The IC50 values for promastigote and amastigote forms were calculated by non-linear
regression analysis from Kc values at concentrations ranging between 1 and 100 µM and are shown in
Table 1A, which also includes the IC50 of Glucantime (Glu), a frequently used reference drug. Also,
we have determined the toxicity values against J774.2 murine macrophages. The selectivity index
values (SI, IC50 macrophage cell toxicity/IC50 of promastigote or amastigote forms of the parasite) and
the times by which the tested compounds exceed the SI value of Glu are shown in Table 1B. Taking into
consideration the fact that amastigote forms are the ones present in mammalian hosts, the IC50 and SI
achieved against this parasitic form were determining for us to carry on with subsequent assays.
Figure 1. Chemical structure of the tested polyaminic compound complexes.
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We found that six compounds (3, 5, 6, 7, 8 and 10) were effective against all three Leishmania spp.
(Table 1). However, 3 remained slightly below the cut-off value (drug SI 20 or more times higher than
that of the reference drug as hit activity criteria proposed by [18]) for L. donovani. Five compounds (3, 5,
6, 7, and 10) presented 2 to 30-fold lower IC50 values against amastigotes than Glu in all three Leishmania
spp. Still, we could observe some species-specificity in the in vitro effectiveness of the compounds.
Compounds 6, 7 and 8 were from 8 to 11-fold more effective against L. donovani amastigotes than
against L. braziliensis and L. infantum amastigotes. On the other hand, 3 and 5 manifested an efficacy 2
and 4 times higher in L. infantum amastigotes compared to the other Leishmania spp. The last compound
of this subseries, 10, was equally effective in all three target species. All subsequent tests were carried
out for only the most leishmanicidal compounds (3, 5, 6, 7, 8 and 10 for L. braziliensis and L. infantum,
and 5, 6, 7, 8 and 10 for L. donovani).
After the initial in vitro studies we were interested in finding out if the six most leishmanicidal
compounds could also prevent the infection of host cells. For this reason, we conducted an assay in
which the J774.2 macrophages were exposed to the metacyclic promastigotes and the compound at
IC25 concentration at the same time. The propagation of the parasitic infection was determined by
measuring the infection rate and the average number of amastigotes per macrophage cell present
during the 10-day treatment period. In addition, the endocytic (short-time of infection) and infection
(long-time of infection) indexes were calculated. The control samples did not include any inhibitory
compounds, so, the last day the infection rates in L. braziliensis, L. donovani and L. infatum reached 72,
63 and 62%, respectively (Figures 2A, 3A and 4A).
In L. braziliensis, the two compounds that caused the highest infectivity inhibition were 5 and
6 (inhibition of 81 and 74%) that caused a decrease in amastigote count of 76 and 63%, respectively.
As is shown in Figure 2, all the compounds were much more effective than the reference drug, Glu
(infectivity reduction of 36%). These two compounds were the most effective against L. infantum,
as well, originating an infectivity inhibition of 84 and 77%, and an average amastigote count reduction
of 76 and 70% (Figure 4).
The compound that manifested the highest inhibitory capacities was 7 against L. donovani
(Figure 3). It confirmed its inhibitory capacities against L. braziliensis and L. infantum, but the effect was
not so powerful, confirming the species-specificity we suspected. The infectivity reduction reached
88% and caused an amastigote per macrophage cell count reduction of 74%. In general, the onset
of all compounds against the subgenus Viannia (L. braziliensis) was slower than against Leishmania
(L. donovani and L. infantum). The decline in the infection rate of L. braziliensis started to appear between
days 4 and 6 (Figure 2A,B).
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Table 1. In vitro activity, toxicity (A) and selectivity index (B) found for the polyaminic compound complexes on extracellular and intracellular forms of Leishmania spp.
Compounds
IC50 µM a
Toxicity IC50
Macrophage (µM)
Leishmania infantum Leishmania braziliensis Leishmania donovani
Promastigote
Forms
Amastigote
Forms
Promastigote
Forms
Amastigote
Forms
Promastigote
Forms
Amastigote
Forms
Glucantime® 18.0 ± 3.1 24.2 ± 2.6 25.6 ± 1.6 30.4 ± 6.1 27.3 ± 4.3 33.3 ± 3.7 15.20 ± 1.3
1 18.5 ± 1.6 20.5 ± 1.8 22.3 ± 0.6 21.3 ± 0.9 28.6 ± 5.8 12.5 ± 2.7 37.9 ± 4.2
2 52.6 ± 3.1 57.5 ± 2.6 37.2 ± 1.9 12.5 ± 1.5 19.7 ± 1.7 16.3 ± 2.5 105.6 ± 8.8
3 8.5 ± 0.4 3.7 ± 1.6 9.3 ± 0.3 8.7 ± 0.6 28.6 ± 3.5 11.7 ± 1.3 98.5 ± 6.3
4 27.4 ± 0.7 24.7 ± 1.2 26.4 ± 0.7 19.4 ± 1.7 60.2 ± 7.1 29.9 ± 1.6 60.3 ± 3.3
5 1.3 ± 0.1 2.3 ± 0.8 3.5 ± 0.6 8.8 ± 1.3 6.8 ± 0.2 10.7 ± 0.8 97.2 ± 3.8
6 7.3 ± 0.1 10.2 ± 1.5 10.1 ± 3.1 11.7 ± 1.1 4.0 ± 0.1 1.3 ± 0.4 137.6 ± 7.4
7 12.3 ± 2.2 9.0 ± 0.4 11.7 ± 0.8 8.5 ± 0.3 8.1 ± 3.9 1.1 ± 0.2 172.1 ± 11.3
8 83.0 ± 9.9 22.5 ± 3.1 73.8 ± 3.6 21.7 ± 1.4 31.7 ± 2.4 1.9 ± 0.3 268.3 ± 16.2
9 71.7 ± 10.0 33.4 ± 3.2 53.2 ± 3.6 30.7 ± 2.5 29.5 ± 3.6 14.5 ± 2.7 100.5 ± 4.8
10 2.6 ± 0.7 10.4 ± 0.1 5.5 ± 0.8 11.9 ± 0.8 18.6 ± 0.9 11.6 ± 3.3 126.1 ± 7.1
11 87.5 ± 5.1 34.6 ± 2.5 60.6 ± 3.8 30.4 ± 1.3 29.5 ± 4.1 19.8 ± 2.6 75.1 ± 4.7
SI b
Leishmania infantum Leishmania braziliensis Leishmania donovani
Promastigote
Forms
Amastigote
Forms
Promastigote
Forms
Amastigote
Forms
Promastigote
Forms
Amastigote
Forms
Glucantime® 0.8 0.6 0.6 0.5 0.6 0.5
1 2.1 (3) 1.8 (3) 1.7 (3) 1.8 (4) 1.3 (2) 3.0 (6)
2 2.0 (2) 1.8 (3) 2.8 (5) 8.4 (17) 5.4 (9) 6.5 (13)
3 11.6 (14) 26.6 (44) 10.6 (18) 11.3 (23) 3.4 (6) 8.4 (17)
4 2.2 (3) 2.4 (4) 2.3 (4) 3.1 (6) 1.0 (2) 2.0 (4)
5 74.8 (93) 42.3 (70) 27.8 (46) 11.0 (22) 14.3 (24) 9.1 (18)
6 18.8 (24) 13.5 (22) 13.6 (23) 11.8 (24) 34.4 (57) 105.8 (212)
7 14.0 (17) 19.1 (32) 14.7 (25) 20.2 (40) 21.2 (35) 156.5 (313)
8 3.2 (4) 11.9 (20) 3.6 (6) 12.4 (25) 8.5 (14) 141.2 (282)
9 1.4 (2) 3.0 (5) 1.9 (3) 3.3 (7) 3.4 (6) 6.9 (14)
10 48.5 (61) 12.1 (20) 22.9 (38) 10.6 (21) 6.8 (11) 10.9 (22)
11 0.9 (1) 2.2 (4) 1.2 (2) (5) 2.5 (4) 3.8 (8)
Results are averages of four separate determinations. a IC50 = the concentration required to give 50% inhibition, calculated by non-linear regression analysis from the Kc values at
concentrations employed (from 100 µM to 1 µM). Each drug concentration was tested in triplicate. Values are the means of four separate determinations ± standard deviation. b Selectivity
index = IC50 Macrophage Cell/IC50 extracellular and intracellular form of parasite. In brackets: number of times that compound exceeds the reference drug SI, on extracellular and
intracellular forms of Leishmania spp.
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However, the same reduction of subgenus Leishmania (Figure 3A,B and Figure 4A,B) appeared
between day 2 and 4 for most compounds, with some noticeable exceptions (day 2 for 5, 6 and 7 against
L. donovani, or 0.5 days for 8 against L. infantum).
Evidently, in view of the previous results, the leishmanicidal activity of the compounds was also
visible in endocytic and infective indexes (Figures 2E, 3E and 4E) from the beginning of the treatment,
and maintained until the day 10 after treatment. Moreover, all compounds tested showed endocytic
and infective indexes lower than those obtained for Glu for the three Leishmania spp. Because the
inhibitory effect of all compounds was evident only 2 days after treatment, we can suggest that these
leishmanicidal compounds are fast killing drugs. It is worth mentioning that all compounds tested
against three Leishmania spp. in the present research study exhibited an infection rate capacity up to
3 times higher than Glu.
Figure 2. Leishmania braziliensis infectivity assay. (A,B) Infection rate percentage and (C,D) amastigote
count per macrophage cell. In brackets: percentage of decrease in infection rate/number of
amastigotes per macrophage cell in comparison to the control measured on the last day of the
experiment (peak of infection). (E) Effects of the compounds on the endocytic and infection indexes.
Each drug at IC25 concentration was tested in triplicate. Values are the means of four separate
determinations ± standard deviation.
Molecules 2019, 24, 134 7 of 21
Figure 3. Leishmania donovani infectivity assay. (A,B) Infection rate percentage and (C,D) amastigote
count per macrophage cell. In brackets: percentage of decrease in infection rate/number of
amastigotes per macrophage cell in comparison to the control measured on the last day of the
experiment (peak of infection). (E) Effects of the compounds on the endocytic and infection indexes.
Each drug at IC25 concentration was tested in triplicate. Values are the means of four separate
determinations ± standard deviation.
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Figure 4. Leishmania infantum infectivity assay. (A,B) Infection rate percentage and (C,D) amastigote
count per macrophage cell. In brackets: percentage of decrease in infection rate/number of
amastigotes per macrophage cell in comparison to the control measured on the last day of the
experiment (peak of infection). (E) Effects of the compounds on the endocytic and infection indexes.
Each drug at IC25 concentration was tested in triplicate. Values are the means of four separate
determinations ± standard deviation.
2.3. Studies on the Mechanism of Action
We performed several experiments to elucidate a possible mechanism of action for the six most
active tetradentate compound complexes, according to the SI.
2.3.1. SOD Inhibition
The previous extraordinary results prompted us to evaluate the inhibitory effect of 3, 5–8 and
10 on the SOD activity. We were looking for a compound that would selectively inhibit parasitic
SODs and not their human equivalent. We used promastigotes of Leishmania spp. to obtain Fe-SOD
by cellular disruption and precipitation and assayed the compounds at concentrations ranging from
100 µM to 0.1 µM in each case.
The results are shown in Figure 5. The corresponding IC50 values were calculated and are included
in the same figure. Not all compounds were equally effective against the three Leishmania spp. As can
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be concluded from the figure, 3 is not an SOD inhibitor, since its IC50 values exceeded 100 µM in both
parasitic Fe-SOD and human CuZn-SOD, even causing a greater inhibition in the human isoform.
5 caused notable inhibition in L. donovani Fe-SOD (IC50 = 0.4 µM) but not in other Leishmania spp. 6 is
undoubtedly a potent SOD inhibitor and it showed preference for the parasitic isoforms like we were
looking for. It produced an inhibition from 3 to 44-fold higher than the one of human SOD. The last
three compounds (7, 8 and 10) did not inhibit the CuZn-SOD in the same extent as the Fe-SOD of
Leishmania spp. As it is shown in Figure 5B,D,F, these compounds are very powerful Fe-SOD inhibitors:
from 3 (8 against L. infantum Fe-SOD) to 5000 times (7 against L. donovani Fe-SOD) more effective than
against CuZn-SOD.
Figure 5. SOD inhibition assay. Representation of the inhibition of 3, 5–8 and 10 against: (A,B)
L. braziliensis Fe-SOD (C,D) L. donovani Fe-SOD (E,F) L. infantum Fe-SOD and (G,H) human CuZn-SOD.
Each drug concentration was tested in triplicate. Values are the means of four separate determinations
± standard deviation. In brackets: IC50 value, calculated by non-linear regression analysis.
The most effective compound against L. braziliensis Fe-SOD was 10 and against L. infantum
Fe-SOD were 6 and 7. 7 was also the overall most potent Fe-SOD inhibitor against all Leishmania spp.,
but particularly against L. donovani. Furthermore, it is the least toxic compound for the human isoform.
2.3.2. 1H-NMR
Trypanosomatids catabolizes glucose at a high rate, excreting into the medium partly oxidized
end products such as acetate, succinate, L-alanine or L-lactate [19,20]. Therefore, we cultivated the
promastigotes of L. braziliensis, L. donovani and L. infantum in glucose-rich medium (MTL) for 96 h with
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and without the six most effective compounds (3, 5, 6, 7, 8 and 10) at IC25 concentrations to see if the
compounds altered the usual excretion pattern, and consequently, altered the glucose metabolism.
1H-NMR spectroscopy was used to identify and quantify the fermented metabolites in cell-free media
after parasite culture and to compare with those metabolites found for untreated parasites. Figure 6
shows the variation in metabolic excretion of the four most important excreted metabolites (D-lactate,
L-alanine, acetate and succinate). We considered a variation superior to 10% as significant.
Compound 3 was not assayed against L. donovani for reasons described above. This compound
raised the levels of all excreted metabolites in L. infantum (from 18% for acetate to 32% for succinate),
but only one in L. braziliensis (succinate). This is in agreement with the fact that succinate is the
major excreted metabolite in Leishmania spp. [13]. Compound 5 did not affect lactate levels in any
Leishmania spp. Even we could say that the only affected species is, again, L. infantum (increase in
L-alanine by 42%, in acetate by 39% and in succinate by 36%). Once more, the 6 affected mostly the
metabolism of L. infantum, causing an increase in L-alanine, acetate and succinate, but in a lesser extent
this time.
Figure 6. Variation in metabolic excretion in L. braziliensis, L. donovani and L. infantum exposed to
compounds at IC25 concentrations in comparison to untreated incubated 72 h, and determined by
1H-NMR.
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Both compounds, 5 and 6, caused an increment in L-alanine (12 and 25%, respectively) in
L. donovani. As we said above, the star compound against L. donovani assayed in this study was
7. Once again, the most affected metabolite was L-alanine (increase in 64%), but this time acetate and
succinate were also extremely elevated (superior to 50%). Other Leishmania spp. were not affected in
the same amount.
The two last compounds, 8 and 10, were the most effective against L. braziliensis promastigotes,
altering all detected metabolites from 22 to 43%. Both elevated the acetate excreted by L. donovani
slightly and decreased the same metabolite in L. infantum. 10 also decreased the levels of alanine and
succinate in L. infantum.
2.3.3. Microscopy
The ultra-thin sections of promastigotes of L. braziliensis, L. donovani and L. infantum were
examined at transmission electron microscopy. The promastiogotes were treated with the most
effective compounds in each Leishmania spp.
The promastigotes of L. braziliensis were treated with the compounds 3, 5–8, and 10 (Figure 7B–F),
and we observed quite a lot of alterations in comparison to the untreated control (Figure 7A), with
exception of 5 and 6 which did not cause apparent damage. The promastigote treated with 3 (Figure 7B)
is completely swollen, round and full of empty or lipid vacuoles. In addition, there are a lot of
electron-dense granules and a notable absence of ribosomes. In Figure 7C, we show a similar effect
on the parasite caused by 7. The promastigote seems to be damaged, swollen, and full of vacuoles.
We observed swollen mitochondria, disintegrated kinetoplasts and compound precipitates in the
cytoplasm but not in the exterior in all examined plates. These electron-dense precipitates were
present in the promastigotes treated with 8, also (Figure 7D). The promastigotes were round and
lacked in ribosomes, apart from unrecognizable or swollen mitochondria. The bizarre effect of the
last compound, 10, on L. braziliensis is shown in Figure 7E–F. The parasites seemed to be shrunken or
dehydrated, had irregular morphologies, global electron density and a wavy plasmatic membrane.
There were countless vacuoles (Figure 7F) in the cytoplasm and the kinetoplasts and mitochondria
were swollen, deformed and unrecognizable, and apparently had no mitochondrial cristae.
Equally, we studied the ultrastructural alterations caused by 5–8 and 10 on in vitro cultured
L. donovani promastigotes and compared them to the control (Figure 8A). All tested compounds
confirmed a similar toxic effect as was described above. The promastigotes after the treatment with
6 (Figure 8B) were still alive, but very close to death, showing either altered organelles and no
ribosomes, or many empty vacuoles. In each case, there was a significant damage to the structure
of the mitochondria, and on top of that, they were full of small vesicles and possessed no cristae.
The effect of 7 was very similar in all three Leishmania spp.: a cytoplasmic emptiness, none or a
few ribosomes, swollen and disintegrated mitochondria and abundant lipid and non-lipid vacuoles
(Figure 8C). Promastigotes treated with 8 (Figure 8D), in addition to the damage akin to that described
for 7, contained an expanded and disperse Golgi apparatus. 10 (Figure 8E) exerted the most lethal
end result in L. donovani promastigotes. Dead parasites underwent a nuclear and cytoplasmic lysis,
and they were full of lipid vacuoles. Similarly, 5 (Figure 8F) was equally effective as the latter one,
causing ribosomal destruction, an intense vacuolization and augmentation of mitochondria size by
4 times which stood out among other alterations.
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Figure 7. Ultrastructural images of L. braziliensis promastigotes treated for 72 h at IC25 concentrations
with: (A) untreated control, (B) 3, (C) 7, (D) 8, (E,F) 10. (N) nucleus, (Nu) nucleolus, (R) ribosomes,
(K) kinetoplast, (M) mitochondrion, (G) glycosome, (V) vacuole, (arrow) electron-dense precipitates of
unassimilated compounds, (dashed arrow) irregular morphologies. In all cases scale bar corresponds
to 1 µm.
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Figure 8. Ultrastructural images of L. donovani promastigotes treated for 72 h at IC25 concentrations
with: (A) untreated control, (B) 6, (C) 7, (D) 8, (E) 10, (F) 5. (N) nucleus, (NM) nuclear
membrane, (M) mitochondrion, (F) flagellum, (R) ribosomes, (MT) microtubule, (GA) Golgi apparatus,
(G) glycosome, (CR) cellular rest, (V) vacuole, (LV) lipid vacuole, (VR) vacuole full of rests, (arrow)
dead promastigote. In all cases scale bar corresponds to 1 µm.
Lastly, we studied the alterations on L. infantum promastigotes by TEM. Generally, every
essayed compound (3, 5, 7, 8 and 10) was effective and caused noteworthy structural changes.
Compound 3 induced agglutination in the parasites, some of which were dead and other were
fading, as it is witnessed by a deficiency in ribosomes and by a presence of distended mitochondria
filled with vacuoles and a swollen kinetoplast (Figure 9B,C). Additionally, we noticed an intense
vacuolization, an appearance of concentric myelinic figures which originated most probably from the
degenerated mitochondria, an enlarged Golgi apparatus and an abnormal electron-dense structure in
the nuclei. A similar mitochondrial swelling was observed after treatment with 5 (Figure 9D,E), besides
hypertrophic Golgi apparatus and nuclear membrane separation. The most destructive compounds
were 7, 8 and 10, causing an almost identical outcome. We noticed cytoplasmic membrane ruptures,
abundance of vacuoles, a general lack in ribosomes, swollen mitochondria, disintegrated nuclei and no
cytoplasmic content. The parasites treated with 8 and 10 (Figure 9G,H,I, respectively) showed swelling
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in mitochondria, Golgi apparatus and flagellar pocket, copious lipid vacuoles and in some parasites,
a vesicle attached to the cytoplasmic membrane.
Figure 9. Ultrastructural images of L. infantum promastigotes treated for 72 h at IC25 concentrations
with: (A) untreated control, (B,C) 3, (D,E) 5, (F) 7, (G,H) 8, (I) 10. (N) nucleus, (M) mitochondrion,
(F) flagellum, (R) ribosomes, (MT) microtubule, (GA) Golgi apparatus, (G) glycosome, (K) kinetoplast,
(CR) cellular rest, (V) vacuole, (LV) lipid vacuole, (VE) vesicle, (FP) flagellar pocket, (arrow) dead
promastigote, (dashed arrow) nuclear membrane separation, (dotted arrow) lysed promastigote. In all
cases scale bar corresponds to 1 µm.
3. Discussion
The goal of the present study was to test the ability of Fe and Mn-based bearing polyaminic
ligands, known for their rich redox properties [21–24], and of the polyamine ligands themselves strong
metal chelators, to affect the viability of the parasite.
The best compounds were 3, 5, 6, 7, 8 and 10 which exhibit a remarkable antileishmania effect
and absence of toxicity. Moreover, all assayed compounds were much more effective than the
reference drug (Glu) to prevent the infection of host cells, acting as fast killing drugs. We detected a
subgenera-specificity in regard to the infection. All compounds show a sooner onset against subgenus
Leishmania (L. donovani and L. infantum) than against subgenus Viannia (L. braziliensis). We suspect
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that the difference in protein composition in the membrane [25] of the subgenera may be the cause, but
we will have to investigate this aspect further in the future. A species-specificity of the compounds is
apparent because 5 and 6 impeded the cell infection by L. braziliensis and L. infantum the most, while 7
was most successful against L. donovani.
Regarding the mechanism of action, the most remarkable difference for 3 was the altered amount
of succinate for L. infantum. It is well-known that this increase can indicates a redox stress [26], and not
a direct effect on the glucose metabolism: the main role of succinate is to maintain the redox balance in
the glycosoma via NADH reoxidation, and it is possible that this pathway is increased to maintain it,
with the consequent increase and excretion in succinate as final product [10,23,24,27]. 5 produces a
similar effect for L. infantum, and the excretion of L-alanine and acetate can also be increased as a result
of the enhancement of the succinate pathway [23].
Compound 6 affected mostly the metabolism of L. infantum and L. donovani, causing an increase
in L-alanine, acetate and succinate, but in a lesser extent this time. Since this compound is a powerful
inhibitor of the Fe-SOD of L. infantum, the metabolic alteration can be also a consequence of a
mitochondrial dysfunction associated to this enzymatic inhibition.
As we said above, the star compound against L. donovani assayed in this study was 7. Once again,
the most affected metabolites were L-alanine, acetate and succinate. These results can indicates,
as before, a redox stress. In addition, this compound 7 is a potent Fe-SOD inhibitor that can cause
a mitochondrial dysfunction and be the final cause of the alteration in the metabolic excretion.
The singular behavior of this compound can be tentatively traced to a combination of its strong
chelate nature and its powerful electron donating character, conferred by the dialkylamine moiety.
This molecule has the potential ability to sequester the iron metal center of SOD, disrupting its
activity, and can also generate iron complexes highly active in red-ox processes, further promoting the
oxidative estress.
The two last compounds, 8 and 10, were the most effective against L. braziliensis promastigotes,
altering all detected metabolites. The reasons can be similar to what happens in L. infantum for 3 and
5. This effect can be traced to the strong chelating nature of these polyamines, which may sequester
transition metal ions, generating red-ox active species that disturb the red-ox balance.
Finally, visible ultrastructural alterations showed a cytoplasmic emptiness, none or a few
ribosomes, swollen and disintegrated mitochondria and abundant lipid and non-lipid vacuoles,
an appearance of concentric myelinic figures which originated most probably from degenerated
mitochondria, an enlarged Golgi apparatus and an abnormal electron-dense structure and disintegrated
nuclei. These cytoplasmic effects could be the result of an ineffective metabolization of the compound
by the promastigotes, causing its precipitation in the cytoplasm, mitochondrion damage and an
excessive activation of the Golgi machinery to produce new vesicles which could isolate the polyamines.
The notable absence of ribosomes also indicates poor survival possibilities of the promastigotes.
It should be noted that the alterations observed in the mitochondria may be both consequence
of the damage produced by the inhibition of Fe-SOD for compounds 6 and 7, as consequence of
the powerful oxidizing of these compounds [17] that cause lipid peroxidation and macromolecule
destruction. Then, both may be the cause of the alterations observed in the glucose metabolism.
4. Materials and Methods
4.1. Compounds Under Study
Most of our compounds (1, 3, 4, 5, 6, 7, 8, 9 and 10) have been previously synthesized for organic
synthesis purposes [21,22,28–32]. Compound 11 was purchased from Catexcel (Derby, UK). On the
other hand, 2 has been designed as a structural variant of 11 and synthesized for the first time in this
work. The respective structures are shown in Figure 1.
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Synthesis of Compound 2
Compound 2 was synthesized as follows: TACN2 (labelled as 11; 47.1 mg, 0.14 mmol) was
dissolved in acetonitrile (1 mL). A solution of FeCl2 (36.2 mg, 0.28 mmol) in acetonitrile (2 mL) was
prepared under inert atmosphere. The solution of FeCl2 was added dropwise at room temperature
to the solution of TACN2, the mixture turned pale yellow and was stirred at room temperature
for 1 h. Then, AgClO4 (114.7 mg, 0.55 mmol) was added and the formation of a white precipitate
was observed. The mixture was stirred over 30 min. Afterwards a white powder and a purple
solution were clearly distinguished. The purple solution was filtered through syringe filters (25 mm
Ø) and the white precipitate was washed with CH3CN until the filtrates became colorless. 121 mg of
purple crystals (0.11 mmol, 80%) were obtained after diffusion with diethyl ether. HRMS (CH3CN):
calcd. for [(C18N6H40)Fe2(ClO4)3]+ 749.0466, found 749.0461 (Supplementary data 1). 1H-NMR
(300 MHz, CD3CN): 107.9, 101.1, 63.5, 37.2, 35.0, 32.1, 4.5 ppm (Supplementary data 2). Anal Calcd.
for [(C18H40N6)Fe(CH3CN)3](ClO4)4: C, 29.62%; N, 12.95%; H, 5.07%. Found: C, 28.9%; N, 12.95%;
H, 5.08%. X-Ray structure: 2 has the formula: [C30 H58 Fe2 N12](ClO4)4·(CH3CN), with the following
Unit Cell Parameters: a 11.570(5) b 14.555(6) c 17.298(7), space Group P-1. Crystal data has been
deposited with the Cambridge Crystallographic Database with the CCDC reference number 1047857
(Supplementary Material 3).
4.2. Parasite Strain and Culture
Promastigote forms of three different Leishmania spp., L. donovani (MHOM/PE/84/LC26),
L. infantum (MCAN/ES/2001/UCM-10) and L. braziliensis (MHOM/BR/1975/M2904), were cultured
in vitro in Medium Trypanosomes Liquid (MTL) supplemented with 10% inactivated foetal calf serum
(FCS) in an air atmosphere at 28 ◦C, in Roux flasks (Corning, Manassas, VA, USA) with a surface area
of 75 cm2, according to [33].
4.3. In Vitro Screening Assays
The compounds and the reference drug Glu were dissolved in DMSO (Panreac, Barcelona, Spain)
and tested from 100 µM to 1 µM with 0.1% (v/v) DMSO final concentration in plates. Therefore,
controls were prepared including 0.1% (v/v) of this component, as previously described [33].
4.3.1. Cell Culture and Cytotoxicity Tests
The macrophage line J774.2 [European collection of cell cultures (ECACC) number 91051511] was
derived in 1968 from a tumour in a female BALB/c mouse. Macrophages were grown in humidified
95% air, 5% CO2 atmosphere at 37 ◦C in Minimal Essential Medium (MEM) with 2 mM glutamine and
20% (v/v) inactivated FCS. The cytotoxicity test on macrophages was performed by Flow cytometry
analysis according to a method previously described [34]. Briefly, cells were seeded at a density
of 5 × 104 cells/well in 24-well microplates (Nunc, Naperville, IL, USA). After 48 h incubation,
the medium was removed, and fresh medium was added together with each test compound at
concentrations from 100 µM to 1 µM and cultured in 500 µL/well volumes for 72 h. Thereafter, cells
were recovered by centrifugation, and cell viability was determined by Flow cytometry (FACS Vantage
flow cytometer, Becton Dickinson, San Jose, CA, USA) after incubating the cells with propidium iodide
(100 mg/mL) and fluorescein diacetate (100 ng/mL). The percentage of viability was calculated in
comparison with the control cultures. The toxicity is expressed as the IC50 value and was calculated
using linear regression analysis from the Kc values of the concentrations employed (100-1 µM) [35].
Each drug concentration was tested in triplicate in four separate determinations.
4.3.2. Promastigote Tests: Extracellular Forms
Promastigote forms were collected in the exponential growth phase and seeded at 1 × 105
parasites/mL in 24-well microplates (Nunc, Naperville, IL, USA), after adding each compound at
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concentrations from 100 µM to 1 µM and cultured in 500 µL/well volumes at 28 ◦C. After 72 h
incubation, the leishmanicidal activity was assessed using a Neubauer haemocytometric chamber in
comparison with the control cultures. The leishmanicidal effect is expressed as the IC50 value and
was calculated using linear regression analysis from the Kc values of the concentrations employed
(100-1 µM) [35]. Each drug concentration was tested in triplicate in four separate determinations.
4.3.3. Amastigote Tests: Intracellular Forms
J774.2 macrophages were grown and seeded at a density of 1 × 104 cells/well in 24-well
microplates (Nunc) with rounded coverslips on the bottom and cultured for 48 h in humidified
95% air, 5% CO2 atmosphere at 37 ◦C in Minimal Essential Medium (MEM) with 2 mM glutamine and
20% (v/v) inactivated FCS. Adherent macrophages were infected with metacyclic promastigotes in
the stationary growth phase of L. donovani, L. infantum and L. braziliensis at a multiplicity of infection
(MOI) ratio of 1:10 and maintained for 24 h. Non-phagocytosed parasites were removed by washing,
and after addition of the testing compounds at concentrations from 100 µM to 1 µM, cultured in
500 µL/well volumes. Control cultures were also included. After 72 h incubation, leishmanicidal
activity was assessed based on the number of amastigotes in treated and untreated cultures in
methanol-fixed and Giemsa-stained preparations by analyzing 500 host cells distributed in randomly
chosen microscopic fields. The leishmanicidal effect was calculated as described to determine the
leishmanicidal activity in the promastigote forms [35]. Each drug concentration was tested in triplicate
in four separate determinations.
4.4. Infectivity Assay
Adherent macrophages were grown, seeded and infected with metacyclic promastigotes as
mentioned above. The compounds at IC25 concentrations (calculated using linear regression analysis
from the Kc values of the concentrations employed) were added immediately after infection and
incubation was performed for 12 h at 37 ◦C in humidified 95% air, 5% CO2 atmosphere. in humidified
95% air, 5% CO2 atmosphere at 37 ◦C Non-phagocytosed parasites and drugs were removed by
washing, and then the infected cultures were grown for 10 days, adding fresh culture medium
every 48 h, according to [35]. Amastigotes per macrophage count was determined in methanol-fixed
and Giemsa-stained preparations as mentioned above every 48 h. The infection rate (defined as the
percentage of infected cells), the average number of amastigotes per macrophage, and the endocytic and
infection indexes (calculated by multiplying the infection rate by the average number of amastigotes
per macrophage [36]) were determined. Each drug concentration was tested in triplicate in four
separate determinations.
4.5. Ultrastructural Alterations
Parasites were cultured at a density of 5 × 105 cells/mL with medium containing the tested
compounds at IC25 concentrations. After 72 h at 28 ◦C, the cultures were processed using a technique
previously described [33] and analysed by TEM (LIBRA 120 PLUS, Zeiss, Barcelona, Spain).
4.6. Metabolite Excretion
Cultures of L. donovani, L. infantum and L. braziliensis promastigotes were seeded in culture flaks
at 5 × 105 cells/mL, and after the addition of the compounds at IC25 concentrations at 28 ◦C. Control
cultures were also included. After 72 h of incubation, parasites were centrifuged at 400 × g for 10 min,
and supernatants were collected in order to determine the excreted metabolites by 1H-NMR. Chemical
shifts were expressed in parts per million (ppm) using sodium 2,2-dimethyl-2-silapentane-5-sulphonate
as the reference signal. The One-dimensional 1H-NMR spectra were acquired with a VARIAN DIRECT
DRIVE 400 MHz Bruker spectrometer (Rheinstetten, Germany) with an AutoX probe using D2O as
solvent. The chemical shifts used to identify the respective metabolites were consistent with those
described previously by some of the authors [37]. The spectral region of 1.0–5.5 ppm was bucketed
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into a frequency window of 0.1 ppm. The peak (2.6 ppm) corresponding to DMSO was removed
before binning, and the regions corresponding to water (4.5–5.5 ppm) and glucose (3.4–3.8 ppm)
were excluded during binning to avoid artefacts due to pre-saturation. The aromatic region was
excluded because the signal to noise ratio in this region was poorer in comparison to the aliphatic
region. The resulting integrals were normalised to the working region (1.0–3.4) ppm of the spectrum to
correct for inter-sample differences in dilution. The binning and normalisations were achieved using
Mestrenova 9.0 software (Santiago de Compostela, Spain). The matrix obtained in Mestrenova was
imported into Microsoft Excel (Redmond, WA, USA) for further data analyses.
4.7. Fe-SOD Enzymatic Inhibition
Parasite cells were collected in the exponential growth phase by centrifugation (400g for 10 min).
The pellet obtained after centrifugation was lysated by sonication, processed according to [38] and
obtained the homogenate fraction which contained the parasite Fe-SOD. The protein content was
quantified using the Sigma Bradford test, which uses BSA as a standard (no trace ability was certified for
the BSA standard) [39]. Superoxide dismutase activities were determined using a method previously
described [40], which measures the reduction in nitrobluetetrazolium (NBT) by superoxide ions.
Human CuZn-SOD. Substrates used in these assays were obtained from Sigma Chemical Co. (St. Louis,
MO, USA). Resulting data were analysed using the Newman−Keuls test.
5. Conclusions
In conclusion, we identified compounds 3, 5, 6, 7, 8 and 10 as potential fast killing drugs to fight
against leishmaniasis. These tetradentate compounds exhibited a remarkable antileishmania effect
against the two morphological forms of the parasite, even better than Glu, with a larger spectrum of
action and lower toxicity.
Our studies suggest the possible mechanism of action of some of them: 3 and 5 seem to act at the
glucose metabolism level of L. infantum; 6 and 7 involve the inhibition of the parasite SOD and the
alteration in the glucose metabolism of L. infantum and L. donovani, respectively; 8 affects the glucose
metabolism of L. braziliensis; and 10 damages the cellular ultrastructure on the three Leishmania spp.;
without forgetting the powerful oxidizing of these compounds.
Based on their biological properties (leishmanicidal activity), 5 was the compound that
demonstrated the best activity/selectivity profile against the two morphological forms of the three
Leishmania spp. In general, they are promising molecules for the development of new leishmanicidal
agents that could be implemented into a step further within the preclinical phase. Moreover, due to
their mechanisms of action seems to be different, it merits mention that combined therapies (also using
Glu) should be considered for obtaining improved efficacy.
Therefore, we present drugs for the development of an easy-to-synthesise, water-soluble and
water-stable antileishmanial agents as a promising therapeutic alternative to current treatments.
Supplementary Materials: The following are available online, Figure S1: Crystal structure of
[FeII2(TACN2)(CH3CN)6](ClO4)4 (2). Perchlorate anions have been omitted for clarity. (Selected bond distances:
av. Fe-NCCH3 = 1.946 ± 0.004 Å, av. Fe-NTACN = 2.038 ± 0.014 Å. Figure S2: Additional ultrastructural images of
L. braziliensis promastigotes. Figure S3: Additional ultrastructural images of L. donovani promastigotes. Figure
S4: Additional ultrastructural images of L. infantum promastigotes. Figure S5: 1H-NMR (400 MHz, CD3CN) of 2.
Figure S6: HRMS of 2.
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